W. Todd Penberthy, PhD

Patient selection, proper up-titration, and insurance barriers must be considered by cardiologists and other physicians seeking to treat patients with the new combo medication.

Study results presented at the 2016 Heart Failure Society of America Scientific Meeting show that treatment with omecantiv mecarbil improved cardiac function and quality of life in patients with heart failure.

Physicians must consider a range of factors when initiating treatment with disease-modifying drug therapy and be prepared to switch to another first- or second-line option if the patient fails to respond.

Treating patients with multiple sclerosis who opt to use only supplements and other complementary and alternative approaches requires a great deal of tact and education, and input and support from all members of the multidisciplinary treatment team.